Orum Doses First Patient with ORM-1153
Orum Therapeutics dosed the first patient in a Phase 1 trial of ORM-1153, a CD123-targeted degrader-antibody conjugate carrying a GSPT1 molecular-glue degrader payload, in relapsed or refractory AML and other CD123-positive hematologic malignancies. The…
